

Optimization of Amide-Based Inhibitors of Soluble Epoxide Hydrolase with Improved Water Solubility

In-Hae Kim, Fenton R. Heirtzler, Christophe Morisseau, Kosuke Nishi, Hsing-Ju Tsai, and Bruce D. Hammock*

Department of Entomology and University of California Davis Cancer Center, University of California, One Shields Avenue, Davis, California 95616

Received January 31, 2005

Soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation. 1,3-Disubstituted ureas with a polar group located on the fifth atom from the carbonyl group of urea function are active inhibitors of sEH both in vitro and in vivo. However, their limited solubility in water and relatively high melting point lead to difficulties in formulating the compounds and poor in vivo efficacy. To improve these physical properties, the effect of structural modification of the urea pharmacophore on the inhibition potencies, water solubilities, octanol/water partition coefficients ($\log P$), and melting points of a series of compounds was evaluated. For murine sEH, no loss of inhibition potency was observed when the urea pharmacophore was modified to an amide function, while for human sEH 2.5-fold decreased inhibition was obtained in the amide compounds. In addition, a NH group on the right side of carbonyl group of the amide pharmacophore substituted with an adamantyl group (such as compound **14**) and a methylene carbon present between the adamantyl and amide groups were essential to produce potent inhibition of sEH. The resulting amide inhibitors have 10–30-fold better solubility and lower melting point than the corresponding urea compounds. These findings will facilitate synthesis of sEH inhibitors that are easier to formulate and more bioavailable.

Introduction

In humans, soluble epoxide hydrolase (sEH; EC 3.3.2.3) is involved in the metabolism of endogenous chemical mediators such as arachidonic acid,¹ linoleic acid,² and other lipid epoxides.³ Epoxides of arachidonic acid (epoxyeicosatrienoic acids or EETs) are known as effective modulators of blood pressure.⁴ However, hydrolyzed metabolites of EETs, dihydroxyeicosatrienoic acids (DHETs), generated by sEH diminish this activity.⁴ We have reported that treatment with effective sEH inhibitors significantly reduces the blood pressure of spontaneous hypertensive rats and angiotensin II induced hypertension in rats.^{5–7} Furthermore, male knockout sEH mice have significantly lower blood pressure than wild-type mice,⁸ supporting the role of sEH in blood pressure regulation. In addition, the EETs have demonstrated further vascular protective effects such as antiinflammatory properties in endothelial cells,^{9–12} suppression of reactive oxygen species following hypoxia–reoxygenation,¹³ attenuation of vascular smooth muscle migration,¹⁴ and enhancement of a fibrinolytic pathway.¹⁵ In both cellular and animal models, continued efficacy of EET-mediated hypertension and cardioprotective effects including inflammation control is dependent upon epoxide hydrolysis by sEH,^{2,16} suggesting that the inhibitors of the sEH will be effective therapeutic agents for hypertension, inflammation, and other disorders that can be addressed by changing the in vivo concentration of EET.

We previously reported 1,3-disubstituted ureas (and related carbamates and amides) as very potent and

stable inhibitors of sEH. These compounds are competitive, tight-binding inhibitors with nanomolar K_I values that interact stoichiometrically with purified recombinant sEH.¹⁶ These inhibitors efficiently reduce epoxide hydrolysis in several in vitro and in vivo models.^{6,16,17} However, these dialkyl inhibitors have limited solubility in water and high melting point, which likely affect their in vivo efficacy and make formulation difficult.^{5,18} Recently, we reported that compounds with a polar functional group located on the fifth/sixth atom from the carbonyl group of the urea pharmacophore are potent inhibitors, and their solubility in water is also improved without drop of the inhibition potency.¹⁹ Analysis of the X-ray crystal structure of the murine sEH with 1-cyclohexyl-3-dodecylurea (CDU), a sEH dialkylurea inhibitor, that the urea is bound by hydrogen bonding between the phenol groups of Tyr³⁸¹ and Tyr⁴⁶⁵, and the carbonyl of the urea, while a salt bridge is formed between one of the urea N–H and Asp³³³ (Figure 1).^{20,21} As illustrated in Figure 1, Gln³⁸² and Trp³³⁴, both conserved residues, form a possible hydrogen-bonding site for a polar group present at around the fifth or sixth atom (approximately 7.5 Å) from the urea carbonyl group. The presence of a functionalized group at this position helps improve the binding of the inhibitor to the enzyme due to additional hydrogen binding. However, the positive effect on the solubility in water of the inhibitor is still quite limited (<2 $\mu\text{g/mL}$) and the resulting compounds still have relatively high melting points (>100°C).¹⁹ Therefore, in the present study, we report the effect of changes in the structure of inhibitors functionalized with a polar group on the inhibition potency and physical properties (e.g. water solubility, $\log P$, and melting point), specifically modifying the urea

* To whom correspondence should be addressed at the Department of Entomology. Phone: 530-752-7519. Fax: 530-752-1537. E-mail: bdhammock@ucdavis.edu.





Figure 1. Diagram of the murine sEH active site and a sEH inhibitor: Distance of potential binding interaction from primary urea pharmacophore. The primary pharmacophore consists of a polar carbonyl group, shown in this case as a urea with R = cyclohexyl, adamantyl, or 3-chlorophenyl. The secondary pharmacophore consists of a polar group (ester, ketone, alcohol, or ether) located five/six atoms away from the carbonyl group of the primary pharmacophore.

central pharmacophore to design potent sEH inhibitors with improved solubility in water.

Chemistry

Syntheses. Compounds in Tables 1 and 2, and compounds **5** and **6** in Table 3 were prepared according to the procedures reported previously.¹⁹ The syntheses of 3-chlorophenyl or 1-adamantylcarbamoylpentanoic acid pentyl esters (**7** and **13**) are described in part A of Scheme 1, and 3-chlorophenylacetyl-, 1-adamantylacetyl-, or 1-adamantylcarbamoylaminobutyric acid pentyl ester (**8**, **14**, and **15**) and amides without a polar group (**16** and **17**) were synthesized by the procedures outlined in part B of Scheme 1. Coupling of adipic acid with 3-chloroaniline (for compound **6**) or 1-adamantylamine (for compound **13**) using 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI) and 4-(dimethylamino)pyridine (DMAP) in dichloromethane, followed by alkylation of the acid with bromopentane in the presence of potassium carbonate (K_2CO_3) as a base in dimethylformamide (DMF), yielded compounds **7** and **14**, respectively, in 65% yield.¹⁹ As described in part B of Scheme 1, 3-chlorophenylacetic acid (for compound **8**), 1-adamantylacetic acid (for compound **14**), or adamantane-1-carboxylic acid (for compound **15**) were coupled with ethyl 4-aminobutyrate hydrochloride in the presence of EDCI and DMAP in dichloromethane to give 3-chlorophenyl- or 1-adamantylacetylaminobutyric acid ethyl ester intermediate (45%), which was hydrolyzed with an aqueous solution of 1 N NaOH in ethanol and then alkylated with bromopentane in the presence of K_2CO_3 as a base in DMF to afford compounds **8**, **14**, and **15** in 75–87% yield. For preparation of **16** and **17**, the same coupling reaction as described above (using EDCI

Scheme 1. Syntheses of 3-Chlorophenyl or Adamantan-1-ylcarbamoylpentanoic Acid Pentyl Ester (**7** and **13**) and 3-Chlorophenyl- or Adamantan-1-ylacetylaminobutyric Acid Pentyl Ester (**8** and **14**)^a




^a Reagents: (a) 3-chloroaniline (for compound **7**) or 1-adamantanamine (for compound **13**), EDCI, DMAP, dichloromethane, rt; (b) 1-bromopentane, potassium carbonate, DMF, rt; (c) (1) 3-chlorophenylacetic acid (for compound **8**), 1-adamantanecarboxylic acid (for compound **14**), or 1-adamantanecarboxylic acid (for compound **15**), EDCI, DMAP, dichloromethane, rt, (2) 1 N aq NaOH, ethanol, rt.

and DMAP) was carried out from the corresponding starting materials (1-adamantanamine and dodecanoic acid for compound **16** (93%), and adamantane-1-ylacetic acid and decylamine for compound **17** (88%)).


Compounds **9**, **11**, and **12** were synthesized by the procedures outlined in Scheme 2. Alkylation of succinic anhydride with pentanol and DMAP as a base in DMF,²³ followed by reduction of carboxylic acid with BH_3 -THF complex in THF, provided 4-hydroxybutyric acid pentyl ester (**I**) in 85% yield.²⁴ Reaction of **I** with 3-chlorophenyl isocyanate in DMF yielded **9**, in 50% yield. **I** was also coupled with 3-chlorophenylacetic acid by using isobutyl chloroformate and triethylamine as a base to provide **11** (55%).²⁵ Alkylation of **I** with 4-nitrophenyl chloroformate in the presence of triethylamine as a base in DMF gave 4-nitrophenyl carbonate intermediate (**II**) in 32% yield, and reaction of **II** with 3-chlorophenol and K_2CO_3 as a base in acetonitrile provided **12** in 85% yield.

Scheme 3 shows synthesis of 4-(3-chlorophenoxy-carbonylamino)butyric acid ethyl ester (**10**). Reaction of ethyl 4-aminobutyrate hydrochloride with triphosgene in $NaHCO_3$ aqueous solution and dichloromethane gave 4-isocyanato intermediate (**III**) (95%),²⁶ which was alkylated with 3-chlorophenol in the presence of triethylamine in DMF to afford **10** (45%).

Water Solubility (S, $\mu g/mL$). Water solubility was determined experimentally using the following procedure at 25 ± 1.5 °C. An excess of the test compound (**1**,

Scheme 2. Syntheses of 4-Substituted Butyric Acid Pentyl Esters (**9**, **11**, and **12**)^a

^a Reagents: (a) pentanol, DMAP, DMF, rt; (b) $\text{BH}_3\text{-THF}$ complex, THF, $-10\text{ }^\circ\text{C}$, N_2 ; (c) 3-chlorophenyl isocyanate, triethylamine, DMF; (d) 3-chlorophenylacetic acid, isobutyl chloroformate, triethylamine, DMF, rt; (e) 4-nitrophenyl chloroformate, triethylamine, DMF, rt; (f) 3-chlorophenol, potassium carbonate, acetonitrile, rt.

Scheme 3. Synthesis of 4-(3-Chlorophenoxy-carbonylamino)butyric Acid Ethyl Ester (**10**)^a

^a Reagents: (a) triphosgene, aq NaHCO_3 /dichloromethane, rt; (b) 3-chlorophenol, triethylamine, DMF, rt.

4, **13**, **14**, **16**, and **17** in Table 4) was added to a vial containing sodium phosphate buffer, 0.1 M, pH 7.4 (1 mL), and a suspension of the mixture was equilibrated during 1 h of sonication and 24 h of shaking, followed by centrifugation (5 min, 200g). The water supernatant (2.5 μL) was dissolved in 0.5 mL of methanol, and to the methanol solution was added 0.5 mL of internal standard solution [1-cyclohexyl-3-tetradecylurea (CTU); 1000 ng/mL in methanol]. A regression curve for each compound was obtained from five standard stock solutions ($r = 0.99$) by using LC-MS/MS [a Waters 2790 liquid chromatograph equipped with a 30×2.1 mm 3 μm C18 Xterra column (Waters) and a Micromass Quattro Ultima triple quadrupole tandem mass spectrometer (Micromass, Manchester, UK)]. Then, the absolute amount of each compound was calculated.^{19,30}

Calculated Octanol/Water Partition Coefficients (P) and Water Solubility (log S). The log *P* value estimated by Crippen's method was generated by using CS ChemDraw Ultra version 6.0. On the basis of this log *P* value, log *S* value (solubility in water) was also calculated with the following equation, which has been suggested by Banerjee et al.:²⁹ $\log P = 6.5 - 0.89(\log S) - 0.015(\text{melting point})$.

Enzyme Preparation. Recombinant murine sEH and human sEH were produced in a baculovirus expression system and purified by affinity chromatography.³¹⁻³³

The preparations were at least 97% pure as judged by SDS-PAGE and scanning densitometry. No detectable esterase or glutathione transferase activities, which can interfere with this sEH assay, were observed.³⁴ Protein concentration was quantified by using the Pierce BCA assay using fraction V bovine serum albumin (BSA) as the calibrating standard.

IC₅₀ Assay Conditions. IC₅₀ values were determined as described by using racemic 4-nitrophenyl-*trans*-2,3-epoxy-3-phenylpropyl carbonate as substrate.³⁴ Enzymes (0.12 μM mouse sEH or 0.24 μM human sEH) were incubated with inhibitors for 5 min in sodium phosphate buffer (200 μL), 0.1 M, pH 7.4, containing 0.1 mg/mL of BSA, at 30 $^\circ\text{C}$ before substrate introduction ($[\text{S}] = 40\ \mu\text{M}$). Activity was assessed by measuring the appearance of the 4-nitrophenolate anion at 405 nm at 30 $^\circ\text{C}$ during 1 min (Spectramax 340 PC; Molecular Devices). Assays were performed in triplicate. IC₅₀ is the concentration of inhibitor that reduces enzyme activity by 50% and was determined by regression of at least five datum points with a minimum of two points in the linear region of the curve on either side of the IC₅₀. The curve was generated from at least three separate runs, each in triplicate, to obtain the standard deviation (SD) given in Tables 1-4.

Results and Discussion

1,3-Disubstituted ureas with various alkyl, cycloalkyl, and aryl groups were reported as potent sEH inhibitors.^{16,18,28} These urea inhibitors stabilize endogenous regulatory epoxides in several *in vitro* and *in vivo* models, resulting in the expected biological changes.^{6,16,17} However, the lipophilicity of 1,3-dialkylureas causes limited solubility in water, which probably affects their *in vivo* efficacy.^{18,19} In addition, the stability of the crystals of the urea compounds, indicated by their high melting point, led to a general lack of solubility, even in organic solvents. These poor physical properties of the 1,3-dialkylureas result in undesirable pharmacokinetic properties and difficulty in compound formulation in either an aqueous or oil base.¹⁹

Morisseau et al.¹⁸ showed that the addition of a polar functional group at the end of a long lipophilic aliphatic

Table 1. Inhibition of Mouse and Human sEH by 1-Adamantyl-3-alkylureas

No.	Structure	Mouse sEH ^a	Human sEH ^a
		IC ₅₀ (μM)	
1		0.05±0.01	0.17±0.01
2		0.05±0.01	0.13±0.01
3		0.05±0.01	0.17±0.01
4		0.05±0.01	0.11±0.01

^a Enzymes (0.12 μM mouse sEH or 0.24 μM human sEH) were incubated with inhibitors for 5 min in sodium phosphate buffer (200 μL; pH 7.4) at 30 °C before substrate introduction ([S] = 40 μM). Results are means ± SD of three separate experiments.

Table 2. Inhibition of Mouse and Human sEH by Ureas and the Corresponding Amides Substituted with Liphophilic Groups

No.	R	X	Y	Mouse sEH ^a	Human sEH ^a	mp ^b (°C)
				IC ₅₀ (μM)		
(a-1)		NH	NH	0.06±0.01	0.16±0.02	122
(a-2)		CH ₂	NH	2.1±0.3	4.0±0.2	76
(a-3)		NH	CH ₂	0.11±0.01	1.4±0.2	93
(b-1)		NH	NH	0.07±0.01	0.19±0.01	223
(b-2)		CH ₂	NH	0.58±0.09	2.1±0.1	125
(b-3)		NH	CH ₂	0.56±0.06	38±2	113
(c-1)		NH	NH	0.71±0.04	0.23±0.01	183
(c-2)		CH ₂	NH	0.15±0.01	6.2±0.2	133
(c-3)		NH	CH ₂	1.4±0.1	4.8±0.6	121
(d-1)		NH	NH	0.76±0.02	1.39±0.02	184
(d-2)		CH ₂	NH	3.7±0.1	16±2	126
(d-3)		NH	CH ₂	2.4±0.2	14±2	135
(e-1)		NH	NH	>100	>100	-
(e-2)		CH ₂	NH	>100	>100	-
(e-3)		NH	CH ₂	>100	>100	-

^a Enzymes (0.12 μM mouse sEH or 0.24 μM human sEH) were incubated with inhibitors for 5 min in sodium phosphate buffer (200 μL; pH 7.4) at 30 °C before substrate introduction ([S] = 40 μM). Results are means ± SD of three separate experiments. ^b mp: melting point.

chain (12–13 atoms away from the urea function) of 1-(adamantan-1-yl)-3-alkylureas makes compounds more hydrophilic while retaining their inhibitory potencies. We assume that such polar groups mimic the carboxylic acids of suspected endogenous substrates. Furthermore, we reported recently that urea compounds functionalized with a polar group (e.g. ester (**1**) or alcohol (**2**) in Table 1) located on the fifth atom from the urea carbonyl are as active as nonfunctionalized liphophilic inhibitor (**4**), and the resulting functionalized compounds show a 3-fold better water solubility than the liphophilic inhibitor. As a following structure of compound **1**, an ether derivative (**3**) with a polar group on the sixth atom has also the same inhibition as compounds **1** and **4**, indicating that a polar group located on the fifth and/or sixth atom (Figure 1; termed herein as the secondary pharmacophore, with the urea moiety being the primary pharmacophore) from the urea carbonyl group is effective for preparing potent sEH inhibitors

with improved water solubility.¹⁹ However, relatively high melting point and low water solubility still result in inhibitors that are difficult to formulate and show low bioavailability.

We previously reported that compounds with an amide functionality as the primary pharmacophore show potent inhibitory activity on murine and human sEHs, as well.^{3,18} As described in Table 2, the inhibitory potency (IC₅₀) of amide compounds disubstituted with liphophilic groups was observed in a range of 0.1–38 μM with both enzymes, while the corresponding ureas showed inhibition (IC₅₀) in a range of 0.06–1.4 μM, implying that an amide functionality would be also useful in the synthesis of potent inhibitors. As shown in Table 2, a cyclohexylurea with a substituent of 2-phenylethyl on the 3-position of the urea function (**a-1**) showed very potent inhibition with both murine and human enzymes. As the substituent on the 3-position of the urea function of compound **a-1** was replaced

Table 3. Inhibition of Mouse and Human sEH by 1-(3-Chlorophenyl)-3-substituted alkylureas

No.	Structure	Mouse sEH ^a	Human sEH ^a
		IC ₅₀ (μM)	
5		0.37±0.04	2.06±0.07
6		0.14±0.01	3.1±0.3
7		1.7±0.5	5.9±0.2
8		2.9±0.2	5.0±0.5
9		17.4±0.5	25.2±0.01
10		>100	>100
11		>100	>100
12		>100	>100








^a Enzymes (0.12 μM mouse sEH or 0.24 μM human sEH) were incubated with inhibitors for 5 min in sodium phosphate buffer (200 μL; pH 7.4) at 30 °C before substrate introduction ([S] = 40 μM). Results are means ± SD of three separate experiments.

by 3-chlorophenyl (**b-1**), 4-methoxyphenyl (**c-1**), and phenyl (**d-1**), the potencies were decreased by 2–20-fold on both enzymes. In the urea substituted with 2-hydroxymethylphenyl (**e-1**), no inhibition was obtained. Interestingly, when the urea functionality of compounds **a-1**, **b-1**, **c-1**, and **d-1** was modified to the corresponding amides (**a-d-2** and **-3**), 2–300-fold reduction in inhibition potency was also obtained as observed in urea inhibitors. In addition, the amides (**e-2** and **e-3**) corresponding to the urea (**e-1**) with no inhibition had no inhibitory potency on either enzyme, suggesting that the SAR trend of amide inhibitors substituted with lipophilic groups was similar to that of ureas. Often, a high melting point, like the ones of ureas disubstituted with lipophilic groups, induces bad physical properties such as low solubility in water and organic solvents.¹⁹ The amide derivatives shown in Table 2 have lower melting points (30–100°C) than the corresponding urea compounds, suggesting that functionalities such as amides will be worth examining as the primary pharmacophore to develop potent inhibitors with improved physical properties.

Therefore, to further improve the physical properties of previously reported urea inhibitors, we investigated the effect of structural modification of the urea func-

tionality with amide, carbamate, ester, and carbonate derivatives, as shown in Table 3. Compounds with a 3-chlorophenyl group on one side (**5–12** in Table 3) were first synthesized, because the ultraviolet-dense aromatic group simplifies monitoring their formation and purification, and the corresponding ureas are relatively good sEH inhibitors (**5** and **6**). After optimizing the primary pharmacophore, the aryl substituent can be replaced by an adamantyl group, leading to more potent but generally UV-transparent inhibitors. In general, 3-chlorophenyl derivatives are 2–5-fold less potent than adamantyl derivatives with the recombinant murine and human enzymes.¹⁶ In addition, it was shown in the previous study that an ester (**5**), alcohol (**6**), or ketone located on the fifth atom from the primary urea carbonyl group is a good functionality for the secondary pharmacophore and that among these functionalities the ester functional group can be prepared easily and in a higher yield than the alcohol or ketone. Therefore, the ester functionality was maintained as the secondary pharmacophore in the present study (Table 3). The replacement of the urea function (**5**) by an amide function (**7** and **8**) results in 5-fold loss of inhibition potency for the murine sEH and a 2-fold loss for the human enzyme. Interestingly, for compounds without

Table 4. Inhibition of Mouse and Human sEH by 1-Adamantyl-3-alkylureas

No.	Structure	Mouse	Human	S^b ($\mu\text{g/mL}$)	Log P^c	mp ^d ($^{\circ}\text{C}$)	Log S^e
		sEH ^a					
		IC ₅₀ (μM)					
1		0.05±0.01	0.17±0.01	1.44±0.4	2.77±0.47	114	2.27
13		0.34±0.01	2.4±0.2	15.1±1.8	3.53±0.47	oil	3.32
14		0.05±0.01	0.43±0.02	17.4±2.1	3.66±0.47	oil	3.17
15		2.8±0.3	9.4±0.5	ND ^f	ND ^f	55	ND ^f
4		0.05±0.01	0.11±0.01	0.50±0.1	4.76±0.47	104	0.20
16		0.05±0.01	5.0±0.3	0.42±0.1	5.52±0.47	75	-0.16
17		0.05±0.01	0.10±0.01	0.32±0.1	5.64±0.47	oil	0.94

^a Enzymes (0.12 μM mouse sEH or 0.24 μM human sEH) were incubated with inhibitors for 5 min in sodium phosphate buffer (200 μL ; pH 7.4) at 30 $^{\circ}\text{C}$ before substrate introduction ($[\text{S}] = 40 \mu\text{M}$). Results are means \pm SD of three separate experiments. ^b Experimentally obtained solubility in sodium phosphate buffer (0.1 M, pH 7.4) at $25 \pm 1 \text{ }^{\circ}\text{C}$. Results are means \pm SD of three separate experiments. ^c log P calculated by Crippen's method by using CS ChemDraw 6.0 version. ^d mp: melting point. ^e Solubility in water. It was calculated according to the following equation suggested by Banerjee et al.: $\log P = 6.5 - 0.89(\log S) - 0.015\text{mp}$, where mp is melting point. ^f ND: not determined.

a secondary pharmacophore, at least a 20-fold lower inhibition was observed for amides compared to the corresponding urea inhibitor,¹⁸ underlying the positive effect on inhibitor binding of the secondary pharmacophore. The presence of the nitrogen atom at the left side of the carbonyl group of the amide (**7**) induced 1.5-fold better inhibition than at the right position (**8**) for the murine sEH, while for the human sEH no change in the potency was observed between these two amides. The presence of oxygen to the right side of carbonyl group, yielding carbamate (**9**), dropped the activity by 10-fold, and interestingly, in the carbamate (**10**) with the oxygen in the left of the carbonyl, no inhibition was observed, confirming that a nitrogen atom (N–H) on the left side of the carbonyl group is important for potent inhibition in this series. Replacement of the carbamate nitrogen on the right side of the carbonyl of compound **9** by a methylene carbon (ester, **11**) resulted in total loss of inhibition for both murine and human sEHs. Moreover, the structure with two oxygen atoms on both sides of the carbonyl group (carbonate, **12**) showed no inhibition, confirming that the presence of at least one nitrogen atom (N–H) in the primary pharmacophore is essential for inhibiting sEHs. These results overall agreed with previous observation by Morisseau et al.

that at least one free amine (N–H) of the urea function is necessary for the inhibition potency.¹⁶

The data in Table 3 indicate that the best functionality for direct inhibition of pure sEH for the primary pharmacophore is a urea (**5** and **6**); however, good inhibition was obtained with amides (**7** and **8**). So the amide functionality was maintained as primary pharmacophore, and the 3-chlorophenyl group on the left side of the amide function was then replaced by a potent adamantyl group. As shown in Table 4, the adamantyl substitution on the left side of the amide pharmacophore increased inhibitor potency 2–50-fold (**13** and **14**) over that of the 3-chlorophenyl analogue (**7** and **8**) for both enzymes, indicating that a bulky cycloalkyl group is a more efficient substituent of the amide pharmacophore than an aryl group for inducing potent inhibition, which is consistent with previous results obtained for urea derivatives.¹⁹ A nitrogen atom present on the right side of the carbonyl of the amide function (**14**) produced 10- and 5-fold better inhibition on murine and human sEHs, respectively, than that on the left side of the carbonyl group (**13**). Similarly, the right side nitrogen atom in the lipophilic amide analogue (**17**) induced 50-fold better inhibition on human sEH than the nitrogen atom on the left side of carbonyl group (**16**), while

no change in inhibition potency on the murine sEH was observed with either compound (**16** and **17**). On the other hand, in compounds with a cyclohexyl group on one side of the amide function in Table 2 and compounds **6** and **7** substituted with a 3-chlorophenyl group, no reasonable changes in the inhibition potency between the amide functions as that shown in adamantyl derivatives (**13**, **14**, **16**, and **17**) were obtained, suggesting that a bulky adamantyl group makes a nitrogen atom present on the right side of the amide function more optimal for producing potent inhibition than the left side nitrogen atom. Interestingly, the same inhibition potency as observed for urea **1** was obtained for amide **14** for the murine sEH, while for the human sEH a 2.5-fold lower inhibition was observed for the amide inhibitor (**14**) over the urea analogue (**1**). Furthermore, the activities obtained for compounds **14** and **1** are as potent as the enzyme inhibition observed for the lipophilic urea **4**, suggesting that structural modifications of the urea primary pharmacophore can be effective in producing potent inhibitors for murine and human enzymes in the presence of a secondary pharmacophore. In addition, the amide function of compound **15**, without a methylene carbon between the adamantane and amide groups, dropped the inhibition 50- and 20-fold for murine and human sEHs, respectively, implying that a methylene carbon present between those groups is important to make the amide inhibitors potent.

The water solubility of these inhibitors was experimentally measured (Table 4). Around 10-fold better solubility was obtained for compounds **13** and **14** with the amide primary pharmacophore than with the urea functionality (**1**). However, no improvement in water solubility was observed in nonfunctionalized compounds with the amide primary pharmacophore (**16** and **17**) compared to the corresponding urea (**4**). When integrated, these results indicate that a big improvement in water solubility can be gained when the lipophilic tail is functionalized with the secondary pharmacophore and when the primary pharmacophore is an amide. As expected, decreased $\log P$ values (~ 3) and much lower melting points (oils) were obtained in the functionalized amide inhibitors (**13** and **14**), indicating that the amide function of substituted inhibitors improved solubility in water and that the calculated $\log P$ values and melting points are useful factors to estimate water solubility, which is a result consistent with that previously reported in our lab.¹⁹ The $\log P$ values of neutral immiscible liquids generally run parallel with their water solubility; however, estimating solubility of solids is complex, because it depends on the energy required to break the crystal lattice. Banerjee et al. have suggested an empirical equation [$\log P = 6.5 - 0.89(\log S) - 0.015\text{mp}$] to relate solubility, melting point (mp), and $\log P$: it is possible to have compounds with high $\log P$ values that are still relatively soluble because of their low melting point. Similarly, it is possible to have a low $\log P$ compound with a high melting point that is very insoluble in both aqueous and organic solutions.²⁹ As shown in Table 4, a 10-fold increase in calculated water solubility ($\log S$), which was determined according to the above equation, was obtained in functionalized amide inhibitors (**13** and **14**) compared to the corresponding urea (**1**), which was consistent with the

solubility obtained experimentally. However, consistency between calculated and experimentally determined solubility was not observed for the higher melting compounds lacking the secondary pharmacophore. These data suggest that Banerjee's equation might be limited to estimating the water solubility of more polar compounds with lower melting points.

This investigation was directed toward producing potent sEH inhibitors with improved physical properties (e.g. solubilities and melting points). We found that no loss of inhibition potency for sEHs was observed when the urea primary pharmacophore was replaced with an amide functionality, as long as an ester secondary pharmacophore is present on the fifth atom from the carbonyl of the primary pharmacophore. Under these conditions for the primary pharmacophore, a 10- and 5-fold better inhibition of murine and human sEHs, respectively, is obtained if the nitrogen of the amide function is placed on the right of the carbonyl. Furthermore, the presence of a methylene carbon between the amide function and a bulky cycloalkyl group (compound **14**) is essential to produce potent amide inhibitors. In addition, the resulting amide inhibitors had 10–30-fold better solubility in water and lower melting point than the corresponding urea compounds. Also in general there is a predictive correlation between the structure–activity relationships (SARs) among compounds with a urea and amide central pharmacophore. The ester derivatives at the secondary pharmacophore provide a facile synthetic route to exploring the steric and electronic effects of the right distal structural components on enzyme binding. However, it is likely that an unhindered ester would be too unstable in vivo to give effective blood levels. However, such compounds may prove valuable as soft drugs that can be administered directly to the target tissue such as skin, air way, or intestinal mucosa. These findings are important for the design of potent inhibitors with improved physical properties that will lead to obtaining intravenous or orally available therapeutic agents for hypertension, inflammation, and other disorders that can be addressed by changing the in vivo concentration of chemical mediators that contain an epoxide.

Experimental Section

Syntheses. All melting points were determined with a Thomas-Hoover apparatus (A. H. Thomas Co.) and are uncorrected. Mass spectra were measured by LC–MS/MS (Waters 2790) using positive mode electrospray ionization. Elemental analyses (C, H/N) were performed by Midwest Microlab, IN; analytical results were within $\pm 0.4\%$ of the theoretical values for the formula given unless otherwise indicated. ¹H NMR spectra were recorded on a QE-300 spectrometer, using tetramethylsilane as an internal standard. Signal multiplicities are represented as singlet (s), doublet (d), double doublet (dd), triplet (t), quartet (q), quintet (quint), multiplet (m), broad (br), and broad singlet (brs). Synthetic methods are described for representative compounds.

5-(3-Chlorophenylcarbamoyl)pentanoic Acid Pentyl Ester (7). To a solution of adipic acid (0.5 g, 3.42 mmol) and DMAP (0.42 g, 3.42 mmol) in dichloromethane (30 mL) and DMF (3 mL) was added 3-chloroaniline (0.44 g, 3.42 mmol) at room temperature. After stirring 10 min, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.65 g, 3.42 mmol; EDCI) was added portionwise to the mixture at room temperature. The reaction was stirred for 12 h. A 1 N aqueous HCl solution (20 mL) was poured into the reaction mixture, and

5-(3-chlorophenylcarbonyl)pentanoic acid was extracted with dichloromethane (30 mL). The organic solution was washed with water (50 mL), dried over Na_2SO_4 , and concentrated. This residue was used for the next reaction without further purification.

To the solution of the above carbamoylpentanoic acid (0.72 g, 2.80 mmol) in DMF (15 mL) was added K_2CO_3 (0.58 g, 4.21 mmol) and 1-bromopentane (0.64 g, 4.21 mmol) at room temperature. After stirring for 12 h, the product was extracted with ether (30 mL), and the ether solution was washed with an aqueous solution of 1 N NaOH (15 mL) and water (40 mL), dried over Na_2SO_4 , and concentrated. The residue was purified using silica gel column chromatography (hexane:ethyl acetate = 5:1) to afford **7** (0.59 g, 65%): $^1\text{H NMR } \delta$ (CDCl_3) 0.91 (3H, t, $J = 6.9$ Hz), 1.29–1.37 (4H, m), 1.60–1.66 (2H, m), 1.70–1.78 (4H, m), 2.35–2.43 (4H, m), 4.08 (H, t, $J = 6.9$ Hz), 7.05–7.09 (1H, m), 7.21–7.23 (1H, m), 7.37–7.40 (1H, m), 7.52–7.55 (1H, m), 7.68 (1H, s); LC–MS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{24}\text{ClNO}_3$ [$\text{M} + \text{H}$] $^+$ 326.14, found [$\text{M} + \text{H}$] $^+$ 326.16, mp 82 °C. Anal. ($\text{C}_{17}\text{H}_{24}\text{ClNO}_3$) C, H, N.

Compound **13** was prepared with the same method used for the preparation of compound **7** using adamantylamine instead of 3-chloroaniline: $^1\text{H NMR } \delta$ (CDCl_3) 0.91 (3H, t, $J = 6.9$ Hz), 1.29–1.43 (4H, m), 1.64–1.69 (12H, m), 1.94–1.98 (6H, m), 2.06–2.13 (5H, m), 2.32 (2H, t, $J = 6.9$ Hz), 4.06 (H, t, $J = 6.9$ Hz), 5.16 (1H, s); LC–MS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{35}\text{NO}_3$ [$\text{M} + \text{H}$] $^+$ 350.26, found [$\text{M} + \text{H}$] $^+$ 350.30. Anal. ($\text{C}_{21}\text{H}_{35}\text{NO}_3$) C, H, N.

4-[2-(3-Chlorophenyl)acetylaminobutyric Acid Pentyl Ester (8). To a solution of 3-chlorophenylacetic acid (0.5 g, 2.93 mmol) and DMAP (0.36 g, 2.93 mmol) in dichloromethane (30 mL) was added ethyl 4-aminobutyrate hydrochloride (0.49 g, 2.93 mmol) at room temperature. After stirring for 10 min, EDCI (0.56 g, 2.93 mmol) was added portionwise to the mixture at room temperature. The reaction was stirred for 12 h. A 1 N aqueous HCl solution (20 mL) was poured into the reaction mixture, and 4-[2-(3-chlorophenyl)acetylaminobutyric acid ethyl ester was extracted with ether (30 mL). The ether solution was washed with water (50 mL), dried over Na_2SO_4 , and concentrated. To the residue dissolved in ethanol (10 mL) was added 1 N aqueous NaOH solution (6 mL), and after 12 h of stirring at room temperature, the product was extracted with dichloromethane (30 mL). The organic solution was washed with water (30 mL), dried over Na_2SO_4 , and concentrated to give 4-[2-(3-chlorophenyl)acetylaminobutyric acid (0.6 g, 80%). A mixture of this acid (0.6 g, 2.35 mmol), K_2CO_3 (0.49 g, 3.52 mmol), and 1-bromopentane (0.53 g, 3.52 mmol) in DMF (20 mL) was stirred overnight at room temperature. The product was extracted with ether (40 mL), and the ether solution was washed with water (50 mL), dried over Na_2SO_4 , and concentrated. The residue was purified using silica gel column chromatography (hexane:ethyl acetate = 3:1) to afford **8** as an oil (0.74 g, 97%): $^1\text{H NMR } \delta$ (CDCl_3) 0.91 (3H, t, $J = 6.9$ Hz), 1.26–1.33 (4H, m), 1.59–1.63 (2H, m), 1.80 (2H, quint, $J = 6.9$ Hz), 2.31 (2H, t, $J = 6.9$ Hz), 3.27 (2H, q, $J = 6.9$ Hz), 3.52 (2H, s), 4.04 (2H, t, $J = 6.9$ Hz), 5.72 (1H, s), 7.13–7.17 (2H, m), 7.27–7.30 (2H, m); LC–MS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{24}\text{ClNO}_3$ [$\text{M} + \text{H}$] $^+$ 326.14, found [$\text{M} + \text{H}$] $^+$ 326.15. Anal. ($\text{C}_{17}\text{H}_{24}\text{ClNO}_3$) C, H, N.

Compounds **14** and **15** were prepared with the same method used for the preparation of compound **8** using 1-adamantylacetic acid or adamantane-1-carboxylic acid instead of 3-chlorophenylacetic acid. Compound **14**: $^1\text{H NMR } \delta$ (CDCl_3) 0.91 (3H, t, $J = 6.9$ Hz), 1.29–1.35 (4H, m), 1.35–1.72 (14H, m), 1.84 (2H, quint, $J = 6.9$ Hz), 1.91 (2H, s), 1.97 (3H, m), 2.37 (2H, t, $J = 6.9$ Hz), 3.29 (2H, q, $J = 6.9$ Hz), 4.07 (2H, t, $J = 6.9$ Hz), 5.66 (1H, s); LC–MS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{35}\text{NO}_3$ [$\text{M} + \text{H}$] $^+$ 350.26, found [$\text{M} + \text{H}$] $^+$ 350.29. Anal. ($\text{C}_{21}\text{H}_{35}\text{NO}_3$) C, H, N.

Compound **15**: $^1\text{H NMR } \delta$ (CDCl_3) 0.91 (3H, t, $J = 6.9$ Hz), 1.29–1.35 (4H, m), 1.60–1.86 (16H, m), 2.03 (3H, m), 2.35 (2H, t, $J = 6.9$ Hz), 3.29 (2H, q, $J = 6.9$ Hz), 4.07 (2H, t, $J = 6.9$ Hz), 5.85 (1H, s); LC–MS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{33}\text{NO}_3$

[$\text{M} + \text{H}$] $^+$ 336.25, found [$\text{M} + \text{H}$] $^+$ 336.34. Anal. ($\text{C}_{20}\text{H}_{33}\text{NO}_3$) C, H, N.

4-(3-Chlorophenylcarbomoyloxy)butyric Acid Pentyl Ester (9). To a solution of succinic anhydride (3.58 g, 35.7 mmol) and DMAP (4.16 g, 34.0 mmol) in DMF (40 mL) was added pentanol (3.0 g, 34.0 mmol) at room temperature under nitrogen. After stirring for 12 h, succinic acid pentyl ester was extracted with ether (40 mL), and the ether solution was washed with 1 N aqueous HCl solution (20 mL) and water (40 mL), dried over sodium sulfate (Na_2SO_4), and concentrated. The residue was purified by column chromatography on silica gel eluting with hexane and ethyl acetate (3:1) to give the succinic acid pentyl ester (6.07 g, 95%) as an oil. To the solution of this acid in tetrahydrofuran (THF, 60 mL) was added 1 M BH_3 –THF complex (64.53 mL, 64.5 mmol) at -10 °C under nitrogen, and the reaction mixture was allowed to warm to room temperature with stirring. After stirring for 12 h at room temperature, 5% NaHCO_3 aqueous solution (50 mL) was added to the reaction and then the reduced alcohol (**I**) was extracted with ethyl acetate (50 mL). The ethyl acetate solution was dried over Na_2SO_4 and concentrated to give **I** (5.06 g, 90%).

4-Hydroxybutyric acid pentyl ester (**I**; 100 mg, 0.57 mmol) was added to a solution of 3-chlorophenyl isocyanate (88 mg, 0.57 mmol) and triethylamine (0.12 mL, 0.86 mmol; TEA) in DMF (15 mL) at room temperature. The mixture was allowed to stand at room temperature for 12 h, the product was extracted with ether (20 mL), and the ether solution was washed with 1 N aqueous HCl solution (20 mL) and water (30 mL), dried over Na_2SO_4 , and concentrated. The residue was purified by column chromatography on silica gel eluting with hexane and ethyl acetate (5:1) to afford **9** (94 mg, 50%) as a solid: $^1\text{H NMR } \delta$ (CDCl_3) 0.90 (3H, t, $J = 6.9$ Hz), 1.26–1.34 (4H, m), 1.62–1.65 (2H, m), 1.71 (2H, quint, $J = 6.9$ Hz), 2.66 (2H, t, $J = 6.9$ Hz), 2.74 (2H, q, $J = 6.9$ Hz), 4.10 (2H, t, $J = 6.9$ Hz), 7.05–7.08 (1H, m), 7.18–7.22 (3H, m), 7.35 (1H, s); LC–MS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{22}\text{ClNO}_4$ [$\text{M} + \text{H}$] $^+$ 328.12, found [$\text{M} + \text{H}$] $^+$ 328.13; mp 82 °C. Anal. ($\text{C}_{16}\text{H}_{22}\text{ClNO}_4$) C, H, N.

Acknowledgment. This work was supported, in part, by NIEHS Grant R37 ES02710, NIEHS Center for Environmental Health Sciences P30 ES05707, NIH/NIEHS Superfund Basic Research Program P42 ES-04699, NIH/NHLBI R01 HL59699-06A1, UC System-wide Biotechnology Research and Education Training Grant #2001-07, NIEHS Center for Children's Environmental Health & Disease Prevention P01 ES11269, and NIH/NIDDK UC Davis Clinical Nutrition Research Unit P30 DK35747, Pilot Project.

Supporting Information Available: Syntheses and detailed analytical data for compounds **3**, **a-2**, **a-3**, **b-2**, **b-3**, **c-2**, **c-3**, **d-2**, **d-3**, **10-12**, **16**, and **17**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- Zeldin, D. C.; Kobayashi, J.; Falck, J. R.; Winder, B. S.; Hammock, B. D.; Snapper, J. R.; Capdevila, J. H. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. *J. Biol. Chem.* **1993**, *268*, 6402–6407.
- Moghaddam, M. F.; Grant, D. F.; Cheek, J. M.; Greene, J. F.; Williamson, K. C.; Hammock, B. D. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. *Nat. Med.* **1997**, *3*, 562–567.
- Carroll, M. A.; McGiff, J. C. A new class of lipid mediators: Cytochrome P450 arachidonate metabolites. *Thorax* **2000**, *55*, S13–16.
- Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties on the arachidonate monooxygenase. *J. Lipid Res.* **2000**, *41*, 163–181.
- Yu, Z.; Xu, F.; Huse, L. M.; Morisseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. *Circ. Res.* **2000**, *87*, 992–998.

- (6) Imig, J. D.; Zhao, X.; Capdevila, J. H.; Morisseau, C.; Hammock, B. D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. *Hypertension* **2002**, *39*, 690–694.
- (7) Zhao, X.; Yamamoto, T.; Newman, J. W.; Kim, I. H.; Watanabe, T.; Hammock, B. D.; Stewart, J.; Pollock, J. S.; Pollock, D. M.; Imig, J. D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. *J. Am. Soc. Nephrol.* **2004**, *15*, 1244–1253.
- (8) Sinal, C. J.; Miyata, M.; Tohkin, M.; Nagata, K.; Bend, J. R.; Gonzalez, F. J. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. *J. Biol. Chem.* **2000**, *275*, 40504–40510.
- (9) Oltman, C. L.; Weintraub, N. L.; VanRollins, M.; Dellsperger, K. C. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. *Circ. Res.* **1998**, *83*, 932–939.
- (10) Fisslthaler, B.; Popp, R.; Kiss, L.; Potente, M.; Harder, D. R.; Fleming, I.; Busse, R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. *Nature* **1999**, *401*, 493–497.
- (11) Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Antiinflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. *Science* **1999**, *285*, 1276–1279.
- (12) Campbell, W. B. New role for epoxyeicosatrienoic acids as antiinflammatory mediators. *Trends Pharmacol. Sci.* **2000**, *21*, 125–127.
- (13) Yang, B.; Graham, L.; Dikalov, S.; Mason, R. P.; Falck, J. R.; Liao, J. K.; Zeldin, D. C. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. *Mol. Pharmacol.* **2001**, *60*, 310–320.
- (14) Sun, J.; Sui, X.; Bradbury, J. A.; Zeldin, D. C.; Conte, M. S.; Liao, J. K. Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids. *Circ. Res.* **2002**, *90*, 1020–1027.
- (15) Node, K.; Ruan, X.; Dai, J.; Yang, S.; Graham, L.; Zeldin, D. C.; Liao, J. K. Activation of Gs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. *J. Biol. Chem.* **2001**, *276*, 15983–15989.
- (16) Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 8849–8854.
- (17) Newman, J. W.; Denton, D. L.; Morisseau, C.; Koger, C. S.; Wheelock, C. E.; Hinton, D. E.; Hammock, B. D. Evaluation of fish models of soluble epoxide hydrolase inhibition. *Environ. Health Perspect.* **2001**, *109*, 61–66.
- (18) Morisseau, C.; Goodrow, M. H.; Newman, J. W.; Wheelock, C. E.; Dowdy, D. L.; Hammock, B. D. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. *Biochem. Pharmacol.* **2002**, *63*, 1599–1608.
- (19) Kim, I. H.; Morisseau, C.; Watanabe, T.; Hammock, B. D. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. *J. Med. Chem.* **2004**, *47*, 2110–2122.
- (20) Argiriadi, M. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Detoxification of environmental mutagens and carcinogens: Structure, mechanism, and evolution of liver epoxide hydrolase. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 10637–10642.
- (21) Argiriadi, M. A.; Morisseau, C.; Goodrow, M. H.; Dowdy, D. L.; Hammock, B. D.; Christianson, D. W. Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. *J. Biol. Chem.* **2000**, *275*, 15265–15270.
- (22) Dhaon, M. K.; Olsen, R. K.; Ramasamy, K. Esterification of N-protected alpha-amino acids with alcohol/carbodiimide/4-(dimethylamino)pyridine. Racemization of aspartic and glutamic acid derivatives. *J. Org. Chem.* **1982**, *47*, 1962–1965.
- (23) Larsen, S. D.; Barf, T.; Liljebris, C.; May, P. D.; Ogg, D.; O'Sullivan, T. J.; Palazuk, B. J.; Schostarez, H. J.; Stevens, F. C.; Bleasdale, J. E. Synthesis and biological Activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. *J. Med. Chem.* **2002**, *45*, 598–622.
- (24) Yoon, N. M.; Cho, B. T. Rapid reduction of carboxylic acid salts with borane in tetrahydrofuran. *Tetrahedron Lett.* **1982**, *23*, 2475–2478.
- (25) Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ -opioid receptor antagonist into a potent δ agonist and ligands with mixed properties. *J. Med. Chem.* **2002**, *45*, 713–720.
- (26) Weisenfeld, R. B. Synthesis of disiloxanediyl diamines via a facile homocondensation of amino silanols. *J. Org. Chem.* **1986**, *51*, 2434–2436.
- (27) Ellison, R. A.; Lukenbach, E. R.; Chiu, C. Cyclopentenone synthesis via aldol condensation. Synthesis of a key prostaglandin intermediate. *Tetrahedron Lett.* **1975**, *16*, 499–502.
- (28) McElroy, N. R.; Jurs, P. C.; Morisseau, C.; Hammock, B. D. QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. *J. Med. Chem.* **2003**, *46*, 1066–1080.
- (29) Banerjee, S.; Yalkowsky, S. H.; Valvani, S. C. Water solubility and octanol/water partition coefficients of organics. Limitations of the solubility–partition coefficient correlation. *Environ. Sci. Technol.* **1980**, *10*, 1227–1229.
- (30) Watanabe, T.; Hammock, B. D. Rapid determination of soluble epoxide hydrolase inhibitors in rat hepatic microsomes by high-performance liquid chromatography with electrospray tandem mass spectrometry. *Anal. Biochem.* **2001**, *299*, 227–234.
- (31) Grant, D. E.; Storms, D. H.; Hammock, B. D. Molecular cloning and expression of murine liver soluble epoxide hydrolase. *J. Biol. Chem.* **1993**, *268*, 17628–17633.
- (32) Beetham, J. K.; Tian, T.; Hammock, B. D. cDNA cloning and expression of a soluble epoxide hydrolase from human liver. *Arch. Biochem. Biophys.* **1993**, *305*, 197–201.
- (33) Wixtrom, R. N.; Silva, M. H.; Hammock, B. D. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. *Anal. Biochem.* **1998**, *169*, 71–80.
- (34) Dietze, E. C.; Kuwano, E.; Hammock, B. D. Spectrophotometric substrates for cytosolic epoxide hydrolase. *Anal. Biochem.* **1994**, *216*, 176–187.

JM0500929